Scorpius Holdings, Inc. (SCPX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Scorpius Holdings, Inc. (SCPX) trades at $0.001 with AI Score 44/100 (Grade C). Scorpius Holdings Inc. operates as an integrated contract development and manufacturing organization (CDMO) through its subsidiary, Scorpius BioManufacturing. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for SCPX: SCPX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SCPX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SCPX: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Scorpius Holdings, Inc. (SCPX) Healthcare & Pipeline Overview
Scorpius Holdings, Inc. functions as an integrated contract development and manufacturing organization (CDMO) via its Scorpius BioManufacturing subsidiary. The company delivers comprehensive services, encompassing analytical testing, process development, formulation optimization, and clinical biomanufacturing, to pharmaceutical and biotechnology enterprises, supporting their product development lifecycle from pre-clinical stages.
What Is the Investment Thesis for SCPX?
Scorpius Holdings, Inc. operates within the growing contract development and manufacturing organization (CDMO) market, providing integrated services to pharmaceutical and biotechnology companies. The company's comprehensive offering, spanning analytical testing to clinical biomanufacturing, positions it to capitalize on the increasing trend of outsourcing in drug development. Key value drivers include its specialized expertise in biologics manufacturing and its established operational infrastructure in Morrisville, NC. However, the company faces significant financial challenges, evidenced by a market capitalization of $0.00B, a deeply negative profit margin of -668.9%, and a low gross margin of 9.8%. The stock's classification as 'OTC Other' and its extremely low price of $0.00 indicate substantial financial risk and potential for high volatility, further underscored by a negative Beta of -5.66. Investors must closely monitor the company's cash position, financing activities, and its ability to secure and execute new CDMO contracts to improve profitability and financial stability. The transition to its current name in February 2024 represents a strategic pivot, but its success hinges on operational efficiency and market penetration.
Based on FMP financials and quantitative analysis
SCPX Key Highlights
Market Capitalization of $0.00B, indicating its status as a micro-cap company with extremely limited market valuation.
- Profit Margin of -668.9%, reflecting substantial net losses relative to revenue and significant unprofitability.
- Gross Margin of 9.8%, suggesting high cost of goods sold relative to revenue, which impacts overall profitability.
- Beta of -5.66, an unusually high negative value indicating extreme inverse volatility relative to the broader market, suggesting unique company-specific factors or very low trading volume.
- Operates with 90 employees, signifying a relatively small operational scale for an integrated CDMO in the biotechnology sector.
Who Are SCPX's Competitors?
SCPX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SCPX's Key Strengths?
Integrated CDMO service model offering comprehensive support from analytical testing to clinical biomanufacturing.
- Specialized capabilities in supporting pharmaceutical and biotechnology enterprises.
- Established operational base in Morrisville, North Carolina, with a dedicated subsidiary, Scorpius BioManufacturing.
What Are SCPX's Weaknesses?
Significant unprofitability with a profit margin of -668.9% and low gross margin of 9.8%.
- Micro-cap status ($0.00B market cap) and extremely low stock price ($0.0013) indicating high financial risk.
- Listed on the OTC Other tier, implying limited disclosure and potential for low liquidity.
- Highly volatile stock performance indicated by a negative Beta of -5.66.
What Could Drive SCPX Stock Higher?
SCPX catalyst: Potential announcement of new significant contract development and manufacturing (CDMO) agreements with pharmaceutical or biotechnology clients, which could signal revenue growth.
- Expansion or upgrade of biomanufacturing facilities or capabilities by Scorpius BioManufacturing, potentially increasing capacity and service offerings.
- Continued operational execution and delivery of services under existing CDMO contracts, maintaining client relationships and revenue streams.
What Are the Key Risks for SCPX?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Significant financial losses, as evidenced by a profit margin of -668.9%, indicating persistent operational challenges and cash burn.
- High operational costs impacting gross margin (9.8%), suggesting inefficiencies or intense pricing pressure in the CDMO market.
- Inability to secure sufficient financing or capital raises, which could impede growth initiatives and ongoing operations given the company's micro-cap status and unprofitability.
- Intense competition within the CDMO sector from larger, more established players, potentially limiting market share and pricing power.
- High volatility and liquidity issues associated with its OTC Other tier listing, posing significant risks for investors regarding price stability and trade execution.
What Are the Growth Opportunities for SCPX?
- **Expansion in the Biologics CDMO Market:** The demand for biologics, including monoclonal antibodies, cell therapies, and gene therapies, is experiencing significant growth. As an integrated CDMO, Scorpius Holdings is positioned to capitalize on this trend by offering specialized development and manufacturing services for complex biological products. The global biologics market is projected to continue its expansion, driven by new drug approvals and an aging population, creating a sustained need for expert manufacturing partners. By enhancing its capabilities and capacity in this area, Scorpius Holdings can attract a larger share of high-value contracts, leveraging its expertise in downstream process development and clinical biomanufacturing.
- **Increasing Outsourcing by Pharmaceutical and Biotech Firms:** Pharmaceutical and biotechnology companies are increasingly outsourcing R&D and manufacturing to focus on core competencies and reduce overhead costs. This trend provides a substantial growth opportunity for CDMOs like Scorpius Holdings. The company's comprehensive service portfolio, which spans analytical testing, formulation, and pre-clinical support, makes it an attractive partner for firms seeking end-to-end solutions. By strategically marketing its integrated capabilities and demonstrating a strong track record, Scorpius Holdings can secure more long-term contracts and expand its client base, benefiting from the industry-wide shift towards external partnerships.
- **Technological Advancement in Biomanufacturing:** The biomanufacturing industry is continuously evolving with new technologies, such as continuous manufacturing, single-use systems, and advanced analytics. Adopting and integrating these cutting-edge technologies can enhance Scorpius Holdings' efficiency, reduce production costs, and improve product quality, thereby offering a competitive advantage. Investing in state-of-the-art equipment and processes for its Scorpius BioManufacturing subsidiary can attract clients seeking partners with advanced capabilities. This strategic investment can lead to increased contract wins, particularly for novel and complex biological entities, positioning the company at the forefront of biomanufacturing innovation.
- **Strategic Partnerships and Collaborations:** Forming strategic alliances with emerging biotechnology companies or academic institutions can provide Scorpius Holdings with early access to innovative drug candidates and development projects. These partnerships can secure future manufacturing contracts and establish the company as a preferred CDMO for novel therapies. Collaborations can also extend the company's reach into new therapeutic areas or technological niches, diversifying its service offerings and client base. By actively seeking out and nurturing such relationships, Scorpius Holdings can build a robust pipeline of potential projects, ensuring sustained growth and market relevance in a competitive environment.
- **Geographic Market Penetration:** While headquartered in Morrisville, US, there is potential for Scorpius Holdings to expand its client outreach beyond its immediate regional market. Targeting biotechnology hubs in other parts of the United States or even exploring international opportunities could significantly broaden its customer base. This expansion could involve establishing sales and business development teams in key regions or participating in international industry conferences to showcase its integrated CDMO capabilities. By strategically increasing its geographic footprint, Scorpius Holdings can tap into new pools of pharmaceutical and biotechnology companies seeking high-quality, comprehensive manufacturing and development services, driving revenue growth.
What Threats Does SCPX Face?
- Intense competition from larger, more established CDMOs with greater resources and capacity.
- Regulatory changes and compliance requirements in the highly regulated biotechnology industry.
- Challenges in securing sufficient capital and financing to support operations and growth initiatives.
- Risk of client attrition and dependence on a limited number of contracts for revenue generation.
What Are SCPX's Competitive Advantages?
- Integrated service offering, providing end-to-end support from analytical testing to clinical biomanufacturing.
- Specialized expertise in complex biomanufacturing processes, catering to the growing biologics market.
- Established operational infrastructure and facilities in Morrisville, North Carolina, supporting consistent service delivery.
What Does SCPX Do?
Scorpius Holdings Inc., incorporated in 2008 and headquartered in Morrisville, North Carolina, operates primarily as an integrated contract development and manufacturing organization (CDMO) through its key subsidiary, Scorpius BioManufacturing. The company underwent a significant rebranding in February 2024, adopting its current name after previously operating as NightHawk Biosciences, Inc. This strategic evolution underscores its dedicated focus on providing specialized services to the dynamic pharmaceutical and biotechnology sectors. Scorpius Holdings offers a comprehensive and integrated array of services designed to support clients throughout various stages of drug development and manufacturing. These services include critical analytical testing, which is fundamental for ensuring product quality and consistency, alongside advanced downstream process development aimed at optimizing purification and yield. The company also specializes in formulation optimization, a crucial step in enhancing drug stability, efficacy, and delivery. A core offering is clinical biomanufacturing, enabling clients to produce biological products for clinical trials under stringent quality standards. Beyond these core manufacturing services, Scorpius Holdings extends its expertise to pre-clinical and product development support, assisting clients in the early stages of their research and development pipelines. Furthermore, it provides essential analytical assistance for Chemistry, Manufacturing, and Control (CMC) documentation, which is vital for regulatory submissions. The company also performs a variety of bioassays, offering critical data for product characterization and potency assessment. With a team of 90 employees, Scorpius Holdings positions itself as a strategic partner for pharmaceutical and biotechnology enterprises seeking outsourced expertise and infrastructure for complex biological product development and manufacturing.
What Products and Services Does SCPX Offer?
- Operate as an integrated contract development and manufacturing organization (CDMO) through Scorpius BioManufacturing.
- Provide comprehensive analytical testing services for pharmaceutical and biotechnology products.
- Offer downstream process development to optimize purification and yield of biological products.
- Specialize in formulation optimization to enhance drug stability, efficacy, and delivery.
- Conduct clinical biomanufacturing for biological products intended for clinical trials.
- Support clients with pre-clinical and product development activities.
- Provide analytical assistance for Chemistry, Manufacturing, and Control (CMC) requirements.
- Perform various bioassays for product characterization and potency assessment.
How Does SCPX Make Money?
- Generates revenue through fee-for-service contracts for development and manufacturing services.
- Partners with pharmaceutical and biotechnology companies for outsourced R&D and production.
- Offers integrated solutions across the drug development lifecycle, from analytical support to clinical manufacturing.
What Industry Does SCPX Operate In?
Scorpius Holdings, Inc. operates within the Biotechnology sector, specifically as a Contract Development and Manufacturing Organization (CDMO). The CDMO market is characterized by robust growth, driven by pharmaceutical and biotechnology companies increasingly outsourcing their R&D and manufacturing needs to specialized third parties. This trend is fueled by the rising complexity of new drug modalities, the need for specialized expertise, and capital expenditure optimization. Scorpius Holdings' integrated service model, covering analytical testing, process development, formulation, and clinical biomanufacturing, positions it to serve a broad spectrum of clients within this ecosystem. The competitive landscape includes numerous established global CDMOs and smaller, specialized players. Scorpius Holdings differentiates itself through its comprehensive offering and focus on supporting clients from pre-clinical to clinical stages, aiming to capture market share by providing a holistic solution in a highly specialized and regulated industry.
Who Are SCPX's Key Customers?
- Pharmaceutical companies seeking outsourced drug development and manufacturing.
- Biotechnology enterprises requiring specialized biomanufacturing expertise.
- Drug developers in need of analytical, process development, and formulation services.
Company Profile
Scorpius Holdings, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in San Antonio, US. The company is led by CEO Jeff A. Wolf. SCPX has traded publicly since 2013.
How Scorpius Holdings, Inc. Is Valued
Relative to its peer group, SCPX's quantitative score of 44/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for Scorpius Holdings, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -76.0%, showing how much profit it generates from its asset base. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Scorpius Holdings, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Scorpius Holdings, Inc. revenue of about $10.0M for fiscal 2026, with EPS near $-342.00.
SCPX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Integrated CDMO service model offering comprehensive support from analytical testing to clinical biomanufacturing.
- Specialized capabilities in supporting pharmaceutical and biotechnology enterprises.
- Established operational base in Morrisville, North Carolina, with a dedicated subsidiary, Scorpius BioManufacturing.
- Upcoming: Potential announcement of new significant contract development and manufacturing (CDMO) agreements with pharmaceutical or biotechnology clients, which could signal revenue growth.
Bear Case
- Significant unprofitability with a profit margin of -668.9% and low gross margin of 9.8%.
- Micro-cap status ($0.00B market cap) and extremely low stock price ($0.0013) indicating high financial risk.
- Listed on the OTC Other tier, implying limited disclosure and potential for low liquidity.
- Highly volatile stock performance indicated by a negative Beta of -5.66.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SCPX Latest News
No recent news available for SCPX.
SCPX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SCPX.
Price Targets
Wall Street price target analysis for SCPX.
SCPX MoonshotScore
What does this score mean?
The MoonshotScore rates SCPX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jeffrey Alan Wolf
CEO
Jeffrey Alan Wolf serves as the Chief Executive Officer of Scorpius Holdings, Inc., overseeing the company's strategic direction and operational execution. His leadership encompasses the management of the company's 90 employees, guiding the integrated contract development and manufacturing organization (CDMO) through its service offerings to pharmaceutical and biotechnology clients. Specific details regarding his prior career history, educational background, and previous executive roles are not provided in the available information, limiting a comprehensive assessment of his professional journey leading up to his current position at Scorpius Holdings.
Track Record: Under Jeffrey Alan Wolf's leadership, Scorpius Holdings, Inc. adopted its current name in February 2024, signaling a strategic rebranding and renewed focus for the company, previously known as NightHawk Biosciences, Inc. His role involves managing the company's workforce and driving the operations of Scorpius BioManufacturing, its primary subsidiary. Specific achievements, key strategic decisions, or company milestones directly attributable to his tenure beyond the name change are not detailed in the provided data.
SCPX OTC Market Information
Scorpius Holdings, Inc. trades on the OTC Other tier, which represents the lowest and most speculative market tier for over-the-counter securities. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which adhere to strict listing requirements regarding financial health, public float, and corporate governance, companies on the OTC Other tier face significantly fewer regulatory and disclosure obligations. This tier is typically home to companies that do not meet the standards for OTCQX or OTCQB, often due to financial distress, lack of public information, or minimal business operations. Investing in stocks on this tier carries inherently higher risks due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited public disclosure and financial reporting, making it difficult for investors to assess the company's true financial health and operational performance.
- High volatility and potential for significant price fluctuations due to low trading volume and speculative nature.
- Increased risk of fraud and manipulation due to less stringent regulatory oversight compared to major exchanges.
- Potential for delisting or cessation of trading if the company fails to meet even minimal operational or disclosure requirements.
- Difficulty in price discovery and valuation given the lack of comprehensive financial data and analyst coverage.
- Verify any available financial statements and audit reports, scrutinizing revenue, expenses, and cash flow for sustainability.
- Thoroughly research the management team's background, experience, and track record, looking for any red flags.
- Understand the company's core business operations, market position, and competitive landscape in detail.
- Assess the company's capital structure, outstanding debt, and recent financing activities for potential dilution or solvency issues.
- Monitor any regulatory filings or news releases for updates on business developments, legal issues, or changes in leadership.
- Evaluate the stock's trading history, volume, and bid-ask spread to understand liquidity and potential for manipulation.
- Consider the company's ability to transition to a higher OTC tier or a major exchange, which would imply improved financial health and transparency.
- Established in 2008, indicating a history of operation, albeit with a recent name change.
- Operates a primary subsidiary, Scorpius BioManufacturing, suggesting a structured business entity.
- Headquartered in Morrisville, US, providing a physical and identifiable operational base.
- Employs 90 individuals, indicating an active workforce and ongoing business operations.
SCPX Healthcare Stock FAQ
What does the AI Score mean for SCPX?
SCPX holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Scorpius Holdings Inc. operates as an integrated contract development and manufacturing organization (CDMO) through its subsidiary, Scorpius BioManufacturing. It offers a comprehensive suite …
What does Scorpius Holdings, Inc. do?
Scorpius Holdings, Inc. operates as an integrated contract development and manufacturing organization (CDMO) through its subsidiary, Scorpius BioManufacturing. The company provides a comprehensive suite of services to pharmaceutical and biotechnology enterprises, covering the full spectrum from early-stage development to clinical manufacturing. These services include essential analytical testing, advanced downstream process development, and meticulous formulation optimization.
How does Scorpius Holdings, Inc. navigate the competitive CDMO landscape?
Scorpius Holdings, Inc. navigates the competitive CDMO landscape by offering an integrated service model that spans analytical testing, process development, formulation, and clinical biomanufacturing. This comprehensive approach aims to provide clients with a single-source solution, potentially streamlining their drug development processes.
What are the financial risks associated with investing in SCPX, particularly as an OTC-listed micro-cap?
Investing in SCPX carries significant financial risks primarily due to its status as an OTC-listed micro-cap company with challenging financial metrics. The company reported a deeply negative profit margin of -668.9% and a low gross margin of 9.8%, indicating substantial unprofitability and high operational costs.
What are the key factors to evaluate for SCPX?
Scorpius Holdings, Inc. (SCPX) holds an AI score of 44/100 (low). operates within the growing contract development and manufacturing organization (CDMO) market, providing integrated services to pharmaceutical and biotechnology companies. Not financial advice.
How frequently does SCPX data refresh on this page?
SCPX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SCPX's recent stock price performance?
Scorpius Holdings, Inc. (SCPX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated CDMO service model offering comprehensive support from analytical testing to clinical biomanufacturing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SCPX overvalued or undervalued right now?
Scorpius Holdings, Inc. (SCPX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SCPX before investing?
Before investing in Scorpius Holdings, Inc. (SCPX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Competitor data was not provided in the source materials, therefore, the 'competitors' array is empty.
- Specific details on the CEO's background and track record beyond his name and role are limited in the provided data.
- The AI Insight mentioned a focus on cancer immunotherapies; however, the primary business description explicitly identifies the company as an integrated CDMO. The dossier prioritizes the explicit CDMO description for the company's current operational focus.
- Today's date is 2026-06-15 for time-awareness in catalysts and risks.